- Home
- MP vs AAPG Comparison
MP vs AAPG Comparison
Compare MP & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- AAPG
- Stock Information
- Founded
- MP 2017
- AAPG 2009
- Country
- MP United States
- AAPG China
- Employees
- MP N/A
- AAPG N/A
- Industry
- MP Metal Mining
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- MP Basic Materials
- AAPG Health Care
- Exchange
- MP Nasdaq
- AAPG Nasdaq
- Market Cap
- MP 4.0B
- AAPG 3.2B
- IPO Year
- MP N/A
- AAPG 2025
- Fundamental
- Price
- MP $31.47
- AAPG $38.99
- Analyst Decision
- MP Buy
- AAPG Buy
- Analyst Count
- MP 8
- AAPG 1
- Target Price
- MP $27.44
- AAPG N/A
- AVG Volume (30 Days)
- MP 13.7M
- AAPG 13.9K
- Earning Date
- MP 07-31-2025
- AAPG 08-06-2025
- Dividend Yield
- MP N/A
- AAPG N/A
- EPS Growth
- MP N/A
- AAPG N/A
- EPS
- MP N/A
- AAPG N/A
- Revenue
- MP $215,981,000.00
- AAPG $134,352,180.00
- Revenue This Year
- MP $22.01
- AAPG N/A
- Revenue Next Year
- MP $91.48
- AAPG $389.09
- P/E Ratio
- MP N/A
- AAPG N/A
- Revenue Growth
- MP 4.63
- AAPG 341.77
- 52 Week Low
- MP $10.02
- AAPG $16.50
- 52 Week High
- MP $39.10
- AAPG $40.81
- Technical
- Relative Strength Index (RSI)
- MP 58.17
- AAPG N/A
- Support Level
- MP $32.00
- AAPG N/A
- Resistance Level
- MP $36.91
- AAPG N/A
- Average True Range (ATR)
- MP 2.43
- AAPG 0.00
- MACD
- MP -0.19
- AAPG 0.00
- Stochastic Oscillator
- MP 60.45
- AAPG 0.00
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.